Use this link to cite:
https://hdl.handle.net/2183/49822 In Vivo Efficacy of Cefiderocol against Ceftolozane/Tazobactam- and Ceftazidime/Avibactam-Resistant Pseudomonas Aeruginosa Carrying the AmpC E219K Substitution
Loading...
Identifiers
Publication date
Authors
Rodríguez-Coello, Arianna
Outeda-García, Michelle
García-Pose, Andrea
González-Pinto, Lucía
Báez-Barroso, Gabriela Alejandra
Guijarro-Sánchez, Paula
Muras, Andrea
Taltavull, Biel
Fraile-Ribot, Pablo Arturo
Alonso-García, Isaac
Advisors
Other responsabilities
Journal Title
Bibliographic citation
Rodríguez-Coello A, Outeda-García M, García-Pose A, Gonzalez-Pinto L, Báez-Barroso GA, Guijarro-Sánchez P, Muras A, Taltavull B, Fraile-Ribot P, Alonso-Garcia I, Oliver A, Vázquez-Ucha JC, Arca-Suárez J, Bou G, Beceiro A. In vivo efficacy of cefiderocol against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa carrying the AmpC E219K substitution. Antimicrob Agents Chemother. 2026 Oct 7;70(10):e0072426.
Type of academic work
Academic degree
Abstract
[Abstract] Chromosomal AmpC variants selected during ceftolozane/tazobactam or ceftazidime/avibactam therapy may affect cefiderocol activity. We evaluated the impact of the E219K substitution on cefiderocol efficacy using isogenic Pseudomonas aeruginosa pairs in a murine bacteremia model. Cefiderocol achieved greater bacterial reductions in parental isolates than in E219K derivatives, despite susceptible MICs. Cefiderocol failed to achieve stasis against a cefiderocol-resistant isolate. E219K impaired cefiderocol efficacy in vivo, supporting close monitoring of cefiderocol activity against isolates carrying this variant.
Description
Brief report
Editor version
Rights
Attribution 4.0 International
Collections
Except where otherwise noted, this item's license is described as Attribution 4.0 International